Manuscript reference number: THELANCETONCOLOGY-D-12-01519
Title: Glioblastoma multiforme: a report of long-term progression-free survival and overall survival of 8 to 16 years after antineoplaston therapy and review of literature
Dear Dr. Burzynski,
Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to publish it because we believe the message would be better elsewhere
Although the decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter from considering us again in the future
Bob Blaskiewicz postulated during the Google+ Hangout on Saturday, that this is a generic, usual, normal course-of-business rejection letter
NO such example is on Al Gore’s Internet
Whose got one ?
Speak now or forever hold your peace
Josephine Jones (@_JosephineJones) tweeted at.5:21pm – 11.Sep.13:
@Majikthyse @frozenwarning @drpaulmorgan @dianthusmed @oracknows It was about 1hr30 mins into Burzynski Movie II. pic.twitter.com/8n3fQkX0v0
Eric Merola revealed in Burzynski: Cancer Is Serious Business, Part II (2), at (1:29:53), that The Lancet Oncology Peer Review Team D-12-01519, in 2 hours 8 minutes and 51 seconds, refused to publish Burzynski’s 11/26/2012 phase 2 clinical trial Progression-Free Survival (PFS) and Overall Survival (OS) re patients 8 – 16 years after diagnosis, results
Didymus Judas Thomas' Hipocritical Oath Blog 